Results 111 to 120 of about 93,221 (259)

Signalling cell cycle arrest and cell death through the MMR System [PDF]

, 2006
Loss of DNA mismatch repair (MMR) in mammalian cells, as well as having a causative role in cancer, has been linked to resistance to certain DNA damaging agents including clinically important cytotoxic chemotherapeutics.
Brown, R., O'Brien, V.
core   +1 more source

Boron Neutron Capture Therapy at a Crossroads: Translational Gap and Emerging Delivery Agents

Chemistry – A European Journal, EarlyView.
This review surveys recent advances in boron delivery agents for BNCT, emphasizing the shift from classical small molecules to multifunctional nanocarriers and theranostic systems. By integrating targeting, imaging, and therapy, next‐generation boron compounds aim to bridge the gap between (bio)chemical innovation and clinical translation.
Christoph Selg, Evamarie Hey‐Hawkins
wiley   +1 more source

Selective regulation of chemosensitivity in glioblastoma by phosphatidylinositol 3-kinase beta

iScience
Summary: Resistance to chemotherapies such as temozolomide is a major hurdle to effectively treat therapy-resistant glioblastoma. This challenge arises from the activation of phosphatidylinositol 3-kinase (PI3K), which makes it an appealing therapeutic ...
Kevin J. Pridham, Kasen R. Hutchings, Patrick Beck, Min Liu, Eileen Xu, Erin Saechin, Vincent Bui, Chinkal Patel, Jamie Solis, Leah Huang, Allison Tegge, Deborah F. Kelly, Zhi Sheng   +12 more
doaj   +1 more source

In vitro therapy against glioblastoma cells by 3-Dezaneplanocin-A, panobinostat, and temozolomide

Glioma, 2018
Background: Glioblastoma multiforme (GBM) is the most malignant primary brain tumor. Current treatment against this tumor consists of maximal surgical resection without threatening the patient's life, followed by a treatment with temozolomide, with or ...
Javier de la Rosa, Alejandro Urdiciain, Bárbara Meléndez, Juan A Rey, Miguel A Idoate, Javier S Castresana   +5 more
doaj   +1 more source

The small molecule ephrin receptor inhibitor, GLPG1790, Reduces renewal capabilities of cancer stem cells, showing anti-tumour efficacy on preclinical glioblastoma models [PDF]

, 2019
Therapies against glioblastoma (GBM) show a high percentage of failure associated with the survival of glioma stem cells (GSCs) that repopulate treated tumours.
Beirinckx, Filip, Colapietro, Alessandro, Cristiano, Loredana, Delle Monache, Simona, Festuccia, Claudio, Gravina, Giovanni, Lorenzon, Giocondo, Mancini, Andrea, Marampon, Francesco, Martellucci, Stefano, Mattei, Vincenzo, Pujuguet, Philippe, Saniere, Laurent, Sferra, Roberta, van der Aar, Ellen, Vitale, Flora   +15 more
core   +2 more sources

Generation of Allogeneic CAR‐T Circumvents Functional Deficits in Patient‐Derived Autologous Product for Glioblastoma

International Journal of Cancer, EarlyView.
Clinical trials of chimeric antigen receptor T‐cell (CAR‐T) therapies in glioblastoma have shown limited clinical benefits. Whether this may be explained by the basal quality of CAR‐T products, which are currently generated using patient, autologous T‐cells, has been little explored.
Sabra K. Salim, Muhammad Vaseem Shaikh, Jeffrey Wei, William T. Maich, Alisha Anand, Oliver Y. Tang, Minomi K. Subapanditha, Zahra Alizada, Yujin Suk, Manoj Singh, Kui Zhai, Aapti Khanna, Benjamin Brakel, Vassil Dimitrov, Zoya Tabunshchyk, Katie Chan, Kevin R. Brown, Parvez Vora, Donald M. O'Rourke, Zev A. Binder, Chitra Venugopal, Jason Moffat, Sheila K. Singh   +22 more
wiley   +1 more source

Progress of temozolomide in the treatment of recurrent high-grade gliomas

Chinese Journal of Contemporary Neurology and Neurosurgery, 2013
High-grade gliomas are central nervous system malignancies which are difficult to treat. Surgery, temozolomide combined with radiotherapy postoperatively and adjuvant chemotherapy with temozolomide have been established as the standard treatment options ...
Jin-duo LI, Rong JIANG, Jin-huan WANG, Bin WANG, Chun-hua MA, Li-wei SUN, Yuan LÜ, Guo-fang HOU   +7 more
doaj  

Non-Hodgkin Lymphoma after Treatment with Extended Dosing Temozolomide and Radiotherapy for a Glioblastoma: A Case Report

Case Reports in Oncology, 2013
Temozolomide (TMZ) is an alkylating agent, used for the treatment of high-grade gliomas. This case report describes the development of a non-Hodgkin lymphoma in a patient treated with extended-dose temozolomide and radiotherapy.
Laura Van Ginderachter, Tony Cox, Ria Drijkoningen, Ruth Achten, Eric Joosens, Annelies Maes, Koen Theunissen, Jeroen Mebis   +7 more
doaj   +1 more source

Immunocompetent murine models for the study of glioblastoma immunotherapy. [PDF]

, 2014
Glioblastoma remains a lethal diagnosis with a 5-year survival rate of less than 10%. (NEJM 352:987-96, 2005) Although immunotherapy-based approaches are capable of inducing detectable immune responses against tumor-specific antigens, improvements in ...
Bloch, Orin, Clark, Aaron J, Fakurnejad, Shayan, Ivan, Michael E, James, Charles D, Oh, Taemin, Parsa, Andrew T, Safaee, Michael, Sayegh, Eli T, Sun, Matthew Z   +9 more
core   +2 more sources

RTA‐408 Enhances Radiosensitivity and Inhibited Tumor Progression via JNK Pathway in Glioblastoma

The Kaohsiung Journal of Medical Sciences, EarlyView.
ABSTRACT Glioblastoma (GBM) is an aggressive brain tumor with poor prognosis owing to its high invasiveness and resistance to therapy. RTA‐408, a synthetic triterpenoid and nuclear factor erythroid 2‐related factor 2 activator, exhibits anti‐inflammatory and anti‐cancer properties; however, its effects on GBM remain unclear. This study investigated the
Hung‐Pei Tsai, Hao Qin, Yoon Bin Chong, I‐Hsiang Chen, Shih‐Hsun Kuo, Tzu‐Ting Tseng, Ann‐Shung Lieu   +6 more
wiley   +1 more source